Q3 2024 Travere Therapeutics Inc Earnings Call Transcript
Key Points
- Travere Therapeutics Inc (TVTX) reported more than 30% growth in net sales over the last quarter, driven by the successful commercial launch of FILSPARIĀ® for IgA nephropathy.
- The company received full approval for FILSPARIĀ®, which is expected to become foundational care in IgA nephropathy, supported by strong two-year data and updated draft KDIGO guidelines.
- Travere Therapeutics Inc (TVTX) submitted an sNDA to modify the frequency of liver monitoring in the FILSPARI REMS, potentially improving patient access.
- The company is expanding access to FILSPARIĀ® outside the US, with launches in Germany and Austria and temporary marketing approval in Switzerland.
- Travere Therapeutics Inc (TVTX) is preparing for a potential sNDA submission for sparsentan in FSGS, with promising data from the Duet and Duplex studies showing significant proteinuria reduction.
- The company experienced some seasonality and operational disruptions during the third quarter, including taking the sales force out of the field for training.
- Net loss for the third quarter of 2024 was $54.8 million, compared to a net income of $150.7 million in the same period in 2023, largely due to a gain from the sale of bile acid products in the previous year.
- Travere Therapeutics Inc (TVTX) paused enrollment in the phase three harmony study for PCAB FINA due to necessary commercial scale-up process improvements.
- There is uncertainty regarding the FDA's requirements for the sNDA submission for sparsentan in FSGS, as discussions are still ongoing.
- The company faces challenges in educating and reaching a broader group of nephrologists, particularly in community settings, to ensure widespread adoption of FILSPARIĀ®.
Good morning and welcome to the Travere Therapeutics third quarter, 2024 financial results conference call. Today's call is being recorded at this time. I would like to turn the conference over to Nivi Nehra, Vice President of Corporate Communications and Investor Relations. Please go-ahead ma'am.
Thank you, Shelley. Good morning and welcome to Travere Therapeutics third quarter, 2024 financial results and corporate update call.
Thank you all for joining. Today's call will be led by our President and Chief Executive Officer, Eric Dube, Ph. D., will be joined in the prepared remarks by Dr. Jula Inrig, M.D., our Chief Medical Officer, Peter Heerma, our Chief Commercial Officer and Chris Cline, our Chief Financial Officer, Dr William Rote, senior Vice President of Research and Development will join us for the Q&A session.
Before we begin, I'd like to remind everyone that statements made during this call regarding matters that are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investorsā 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
